Restructurings, exit costs, and impairments under 8-K Items 2.05/2.06.
Quanterix Corp announced a restructuring with charges of approximately $1.5 million.
“The Company expects to incur expenses of approximately $1.5 million related to the reduction in force, substantially all of which will be cash expenditures incurred in 2025 for severance.”
Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $1.4 million (approximately 30% of its current employees).
“to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by August 2025. The Company expects to recognize approximately $1.4 million for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash charges.”
3D SYSTEMS CORP announced a restructuring with charges of approximately $6 to $10 million.
“31, 2025 and is expected to deliver in-year savings of $20 million by the end of the Company’s fiscal year. The Company expects to incur aggregate charges of approximately $6 to $10 million predominantly related to employee severance and other one-time costs related to employee benefits. The Company may incur additional charges as it finalizes all of”
10x Genomics, Inc. announced a restructuring with charges of between $5.5 million and $6.5 million (approximately 8% of the Company’s global workforce).
“On May 6, 2025, to decrease its costs and adjust its organizational structure to align with its strategic priorities, the Company committed to a reduction in force that is expected to result in the termination of approximately 8% of the Company’s global workforce. In connection with the reduction in force, the Company currently estimates it will incur between $5.5 million and $6.5 million of costs consisting primarily of cash severance costs which the Company expects to recognize in the second quarter of 2025 and pay by the end of third quarter of 2025.”
Alight, Inc. / Delaware announced a restructuring with charges of approximately $65 million in pre-tax restructuring costs affecting post-divestiture operations.
“expanding our use of artificial intelligence and automation and continued optimization of real estate. The Company currently expects to record in the aggregate approximately $65 million in pre-tax restructuring costs over the duration of the PSP, which includes primarily cash severance payments with an estimated range of $20 million to $30 million and other”
Vor Biopharma Inc. announced a restructuring with charges of approximately $19.3 million affecting clinical and manufacturing operations (147 full-time employees, or approximately 95% of the Company’s current employee base).
“full-time employees, or approximately 95% of the Company’s current employee base (the “Wind Down”). The total costs related to the Wind Down are estimated to be approximately $19.3 million. The Company estimates that it will incur approximately $3.5 million in contract termination and other costs related to the discontinuation of its clinical trials, approximately”
CrowdStrike Holdings, Inc. announced a restructuring with charges of approximately $36 million to $53 million (approximately 500 positions or 5% of the Company’s global workforce).
“On May 6, 2025, the Company announced a strategic plan (the “Plan”) to evolve its operations to yield greater efficiencies as the Company continues to scale its business with focus and discipline to meet its goal of $10 billion in ending ARR. The Plan is expected to result in a reduction of roles representing approximately 500 positions or 5% of the Company’s global workforce. CrowdStrike expects to continue to hire in key strategic areas throughout its fiscal year ending January 31, 2026. CrowdStrike estimates that it will incur approximately $36 million to $53 million in charges in connection with the Plan, of which approximately $7 million is expected to be recognized in the first quarter of fiscal 2026, and substantially all of the remainder of which will be incurred in the second quarter of fiscal 2026.”
Korro Bio, Inc. announced a restructuring with charges of approximately $1.2 million (approximately 20%).
“Korro estimates that it will incur one-time restructuring charges of approximately $1.2 million including employee severance, benefits and related termination costs, the majority of which Korro expects to recognize during the three months ended June 30, 2025.”
biote Corp. announced a restructuring with charges of approximately $0.6 to $0.8 million affecting commercial teams (16 employees).
“maximize value from existing top-tier providers and strengthen accountability and discipline throughout the organization. The Company estimates that it will incur approximately $0.6 to $0.8 million in pre-tax restructuring charges, which represent future cash expenditures for the payment of one-time severance benefits and other associated costs. The Company”
PIXELWORKS, INC announced a restructuring with charges of approximately $0.6 million affecting research and development (approximately 4% reduction in workforce).
“the restructuring to be substantially complete by the end of the second quarter ending June 30, 2025 and expects to incur total estimated restructuring charges of approximately $0.6 million related to employee severance and benefits. The Company expects that these charges will largely be recorded in the second quarter of 2025. As a result of the restructuring, the”
Mersana Therapeutics, Inc. announced a restructuring with charges of Restructuring costs of approximately $4-5 million in cash expenditures for severance, benefit payments, outplacement services and related expenses. affecting all functions (approximately 55% reduction of current employee base).
“On May 6, 2025, Mersana Therapeutics, Inc. (the “Company”) announced the implementation of a strategic restructuring and reprioritization plan. In connection therewith, on May 5, 2025, the Company’s board of directors approved certain expense reduction measures, including the Company’s commitment to a reduction of approximately 55% of the Company’s current employee base across all functions (the “Restructuring”). The Restructuring is expected to be substantially complete by the end of the third quarter of 2025. As a result of the Restructuring, the Company estimates that it will incur approximately $4-5 million in costs resulting from cash expenditures consisting of severance and benefit payments, outplacement services and related expenses.”
Netcapital Inc. announced a impairment with charges of $17,935,476.
“On April 30, 2025, Netcapital Inc. (the “Company”) conducted its quarterly evaluation of equity investments under Accounting Standards Codification (ASC) Topic 321, Investments – Equity Securities . Based on this review, the Company identified multiple investments that were impaired and recognized a total impairment expense of $17,935,476.”
Unity Biotechnology, Inc. announced a restructuring with charges of approximately $3.7 million (a reduction in force affecting all of its employees).
“The Company estimates that it will incur aggregate cash expenses of approximately $3.7 million in connection with the reduction in force, including severance, benefits, and related termination costs, which includes fees to be paid under consulting agreements.”
Li-Cycle Holdings Corp. announced a restructuring with charges of approximately $264,000 affecting Arizona Spoke and Alabama Spoke recycling facilities; Toronto headquarters (approximately 119 positions, representing approximately 50% of the Company’s global workforce).
“On April 30, 2025, the Board of Directors of the Company approved plans to suspend operations at the Company’s Arizona Spoke and Alabama Spoke recycling facilities, as part of its effort to optimize liquidity and support the Company’s sale process. As a result, the Company has furloughed approximately 85 employees at or related to these facilities. In addition, the Company has reduced its workforce at the corporate level by approximately 34 positions, primarily at its Toronto headquarters, effective May 1, 2025. Overall, the Company expects to eliminate approximately 119 positions, representing approximately 50% of the Company’s global workforce. The Company estimates that it will incur total charges of approximately $264,000 in connection with the workforce reduction, with the majority of these charges to be incurred as cash severance payments over the course of the next two months.”
INTERPACE BIOSCIENCES, INC. announced a restructuring with charges of severance costs in the range of $0.5 million to $0.6 million to be recorded primarily in the second quarter of 2025 which is in addition to the $0.2 million pre affecting workforce reduction (reducing its workforce).
“On April 25, 2025, the Company announced implementation of its previously approved restructuring and cost-savings plan to reduce operating costs and better align its workforce with the loss of PancraGEN® (the “Restructuring Plan”).”
ARVINAS, INC. announced a restructuring with charges of approximately $10 million affecting all areas of the Company (approximately 33%).
“On April 30, 2025, the Company's management, pursuant to authority delegated by the Board of Directors of the Company, committed the Company to and approved a reduction of the Company’s workforce by approximately 33% across all areas of the Company, as part of the Company's decision to streamline operations across the organization and enable the efficient progression of the Company’s portfolio. The Company expects the workforce reduction will be substantially completed by the end of the second quarter of 2025. The Company expects that it will incur approximately $10 million in costs in connection with the workforce reduction, which consist of severance and other one-time employee termination benefit expenses, which the Company expects to recognize primarily in the second quarter of 2025.”
PLIANT THERAPEUTICS, INC. announced a restructuring with charges of $3.6 million (approximately 45% of its current employees).
“current employees. The Company expects to substantially complete the workforce reduction by the end of the second quarter of 2025. The Company expects to recognize approximately $3.6 million in total for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash”
OPEN TEXT CORP announced a restructuring with charges of up to approximately $200 million affecting globally (approximately 2,000 positions).
“On April 29, 2025, the Board of Directors of the Company approved an expansion of its previously announced Business Optimization Plan to complete strategic initiatives, integration and simplification following the Micro Focus acquisition, AMC divestiture and other growth and innovation plans including the deployment of AI and automation. The Company expects up to approximately $200 million of additional costs to be incurred to complete this final phase of the Business Optimization Plan, bringing the combined plan up to approximately $260 million. This expansion includes costs associated with workforce reduction due to automation, centralization and simplification, and corresponding facility costs related to a reduction of the Company’s real estate footprint globally. On an overall basis, the expansion is expected to result in a total net reduction of approximately 2,000 positions, an increase of approximately 1,600 positions from the previously announced plan.”
Owens Corning announced a impairment with charges of approximately $360 million affecting GR Business.
“On April 25, 2025, the Company determined that the estimated pre-tax noncash impairment charge related to the sale of the GR Business is expected to be approximately $360 million”
Smurfit Westrock plc announced a restructuring with charges of approximately $99 million affecting U.S. and Germany (Approximately 650 employees).
“The Company expects to incur aggregate (i) pre-tax cash charges of approximately $99 million associated with the Closures, consisting of approximately $42 million in severance payments to former employees and $57 million in other restructuring costs”
Entrada Therapeutics, Inc. announced a restructuring with charges of approximately $2 million affecting research areas (approximately 20%).
“-45, -50, and -51), ocular programs and maturing platform investments. In connection with the new strategic plan, the Company expects to incur aggregate charges of approximately $2 million in total expenses related to the reduction in force, consisting primarily of one-time severance payments and continued healthcare benefits for a specific period of time. The”
SPRUCE BIOSCIENCES, INC. announced a restructuring with charges of approximately $0.9 million (workforce reduction of 55%).
“and expenditures relating to the workforce reduction will not be known until all related activities have been completed. The Company estimates that it will incur approximately $0.9 million in cash charges in connection with the workforce reduction, consisting of expenses related to severance payments and healthcare coverage assistance and related costs. The Company”
Caribou Biosciences, Inc. announced a restructuring with charges of approximately $2.5 million to $3.5 million in total affecting GALLOP phase 1 clinical trial for CB-010 in lupus, AMpLify phase 1 clinical trial for CB-012, and preclinical research (47 employees, or approximately 32% of the Company).
“half of 2027. In connection with the strategic pipeline prioritization and the workforce reduction, the Company currently estimates it will incur expenses of approximately $2.5 million to $3.5 million in total, consisting primarily of cash severance costs, benefits, and transition support services for impacted employees, and future costs to wind down its GALLOP”
Atkore Inc. announced a impairment with charges of approximately $121 million to $162 million affecting high-density polyethylene (HDPE) pipe and conduit products.
“investments, in combination with the Company’s forward-looking cash flow projections. The Company expects to record a pre-tax non-cash impairment charge of approximately $121 million to $162 million in its second quarter results. This charge is not expected to result in future cash expenditures. These preliminary estimated results are subject to revision”
Tempest Therapeutics, Inc. announced a restructuring with charges of approximately $1.5 million (21 of 26 full-time employees).
“that key employees within this group will transition to consulting agreements and continue to be available to the Company. The Company estimates that it will incur approximately $1.5 million of cash expenditures, consisting primarily of one-time severance payments, benefits and other related costs (excluding non-cash charges associated with equity-based”
Mural Oncology plc announced a impairment with charges of $2.0 million to $4.0 million affecting property and equipment.
“Additionally, the Company expects to incur $2.0 million to $4.0 million in non-cash impairment charges associated with property and equipment expected to be sold or otherwise disposed of.”
Mural Oncology plc announced a restructuring with charges of approximately $9.0 million to $10.0 million (approximately 104 positions, or approximately 90%).
“90% (the “Reduction”). The Company expects to substantially complete the Reduction by the end of the second quarter of 2025. The Company expects to incur costs of approximately $9.0 million to $10.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. Additionally, the Company expects to incur $2.0 million to $4.0”
STEM, INC. announced a restructuring with charges of approximately $6.0 million to $6.5 million (approximately 27%).
“On April 9, 2025, the Company announced a reduction in force plan (the “Plan”), as part of the Company’s broader efforts to prioritize investments in software, reduce operating costs, increase efficiency, drive profitable growth and increase stockholder value. The Plan will reduce the Company’s global full-time workforce by approximately 27%. The Company estimates the total cash expenditures associated with the Plan to be approximately $6.0 million to $6.5 million, primarily consisting of severance payments, notice period payments in applicable jurisdictions, employee benefits and related costs.”
MARIN SOFTWARE INC announced a restructuring with charges of between approximately $0.4 million affecting global employees (reduction of the Company’s global employees by 20 employees, representing approximately 30% of the Company’s global empl).
“to substantially complete the April 2025 Restructuring Plan by the end of the quarter ending June 30, 2025. The Company estimates that it will incur between approximately $0.4 million of cash expenditures in connection with the April 2025 Restructuring Plan, substantially all of which relates to severance costs. The Company expects to recognize the majority of”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. announced a restructuring with charges of approximately $5 million in 2025.
“In connection with the plan, the Company estimates that it will incur approximately $5 million in 2025, consisting primarily of employee severance and benefit costs, which will be future cash expenditures.”
Post Holdings, Inc. announced a restructuring with charges of approximately $63.5 to $67.5 million affecting cereal manufacturing facilities in Cobourg, Ontario and Sparks, Nevada (approximately 300 employees).
“and closure of the Facilities is currently expected to be completed by the end of December 2025. The Company currently expects to incur pre-tax charges of approximately $63.5 to $67.5 million in connection with the transfer of production capabilities to other Company locations and closure of the Facilities. Components of the pre-tax charges include”
MAGNACHIP SEMICONDUCTOR Corp announced a restructuring with charges of Plan to shut down Display business, including liquidation of Magnachip Mixed-Signal, Ltd. affecting Display business.
“On April 8, 2025, Magnachip Semiconductor Corporation (the “Company”) announced its plan to shut down its Display business (the “Discontinued Business”), which will include the liquidation of Magnachip Mixed-Signal, Ltd., the Company’s wholly owned subsidiary that operates the Discontinued Business (collectively, the “Liquidation”).”
Clipper Realty Inc. announced a impairment with charges of from approximately $32.0 million to approximately $34.0 million affecting the Property (10 West 65th Street, New York).
“The Company currently estimates that the range of such impairment charges for Investment in Real Estate assets could be from approximately $32.0 million to approximately $34.0 million.”
BRC Group Holdings, Inc. announced a impairment with charges of approximately $68 million to $74 million affecting Nogin Commerce, LLC.
“the Company based on the factors noted above concluded that goodwill and other intangible assets of Nogin were impaired and the charges are estimated to be approximately $68 million to $74 million.”
Five9, Inc. announced a restructuring with charges of approximately $7 million to $9 million affecting global full-time employees (approximately 4%).
“On March 31, 2025, the Board of Directors of the Company approved a reduction in force plan (the “Plan”) as part of the Company’s broader efforts to prioritize investments in key strategic areas, including artificial intelligence, as well as to drive profitable growth in supporting its positive, long-term outlook and increasing shareholder value. On April 3, 2025, the Company commenced execution of the Plan, which is expected to reduce the Company’s global full-time employees by approximately 4%. The Company estimates the cash expenditures associated with the Plan to be approximately $7 million to $9 million, primarily consisting of severance payments, notice period payments in applicable jurisdictions, employee benefits and related costs.”
EnerSys announced a restructuring with charges of approximately $20 million affecting Monterrey, Mexico facility focused on manufacturing flooded motive power batteries (approximately 269 employees).
“a plan to close its facility in Monterrey, Mexico, which focused on manufacturing flooded motive power batteries. EnerSys expects to incur a pre-tax charge of approximately $20 million under this restructuring plan when completed, the majority of which is expected to be recorded in the first half of calendar year 2025, of which $7.6 million is expected to be a”
Lyell Immunopharma, Inc. announced a restructuring with charges of $3.0 million to $4.0 million affecting West Hills manufacturing facility (approximately 73 employees).
“On March 31, 2025, Lyell’s Board of Directors (the “Board”) approved the closure of the West Hills manufacturing facility acquired as part of Lyell’s acquisition of ImmPACT Bio in 2024. The Board also approved the reduction of the Company’s workforce in West Hills by approximately 73 employees related to such closure. In connection with these actions, the Company expects to incur aggregate expenses of between $3.0 million to $4.0 million, related to severance, benefits, payroll taxes, and other workforce reduction costs, which are expected to be recognized primarily in the second and third quarters of 2025.”
RYTHM, Inc. announced a restructuring with charges of costs associated with exit or disposal activities affecting legacy extraction business (nine employees).
“the Company expects to reduce its workforce by nine employees by April 1, 2025 and to dispose of any remaining inventory relating to the Extraction Business”
KULICKE & SOFFA INDUSTRIES INC announced a restructuring with charges of $86 million and $100 million affecting Electronics Assembly (EA) equipment business (between approximately $11 million and $13 million of severance and other employee-related costs).
“of the EA equipment business. As a result of this intended cessation of business, the Company expects to incur total pre-tax charges, including impairments, in the range of $86 million and $100 million. These charges include: • Pre-tax cash expenditures of: (i) between approximately $11 million and $13 million of severance and other employee-related costs, (ii)”
Tenaya Therapeutics, Inc. announced a restructuring with charges of approximately $1.6 million to $2.7 million.
“as planned. Key capabilities to support early research have also been retained. In connection with the Restructuring Plan, Tenaya estimates that it will incur approximately $1.6 million to $2.7 million of aggregate charges, primarily related to employee cash severance and continuing health benefits. Tenaya expects to recognize substantially all of the charges by”
BioAtla, Inc. announced a restructuring with charges of $0.5 and $0.6 million (approximately 30%).
“On March 27, 2025, the Company announced a workforce reduction of approximately 30%. The foregoing actions were committed to on March 21, 2025 and are intended to streamline the Company’s operating cost structure to support development of its prioritized programs and set the Company up for long-term success. The total cash payments related to this workforce reduction are estimated to be between $0.5 and $0.6 million related to employee severance and benefit costs.”
Nkarta, Inc. announced a restructuring with charges of approximately $5.5 million to $6.5 million (approximately 34% of the Company’s workforce, or 53 positions).
“are expected to extend the Company’s cash runway into 2029. In connection with the implementation of the Reduction, the Company currently estimates it will incur approximately $5.5 million to $6.5 million in expenses, consisting primarily of cash severance costs, benefits, payroll taxes and other termination costs for impacted employees, which the Company expects”
3D SYSTEMS CORP announced a restructuring with charges of approximately $12 to $20 million.
“of at least $50 million by the end of the second quarter of the Company’s fiscal year ending December 31, 2026. The Company expects to incur aggregate charges of approximately $12 to $20 million predominantly related to employee severance (including certain one-time costs related to employee benefits), one-time capital expenditures, and contract termination”
Benson Hill, Inc. announced a restructuring with charges of approximately $1.7 million.
“At this time, the Company expects that the aggregate costs related to such terminations will be approximately $1.7 million.”
O-I Glass, Inc. /DE/ announced a restructuring with charges of approximately $50 million affecting European segment (approximately 170 people).
“other European plants in the Company’s network. Subject to finalization of certain estimates, the Company expects to record charges associated with this closure of approximately $50 million in the first quarter of 2025, primarily for one-time employee separation benefits and other costs related to the closing (of which approximately $50 million relate to future cash”
Elevation Oncology, Inc. announced a restructuring with charges of approximately $3 million affecting entire company (approximately 70%).
“The total cash payments and costs related to this reduction in force are estimated to be approximately $3 million”
ON SEMICONDUCTOR CORP announced a impairment with charges of pre-tax non-cash impairment charges of between $600 million and $700 million affecting certain onsemi manufacturing facilities.
“On March 17, 2025, as part of the restructuring plan and cost reduction initiatives previously announced on February 24, 2025, management of ON Semiconductor Corporation (the “ Company ” or “ we ” and, together with its subsidiaries, “ onsemi ”) approved the recognition of pre-tax non-cash impairment charges of between $600 million and $700 million. These impairment charges are for long-lived assets relating to investments in manufacturing equipment at certain onsemi manufacturing facilities pursuant to held-for-sale accounting guidance.”
CARGO Therapeutics, Inc. announced a restructuring with charges of $24.0 million to $29.0 million (approximately 90%).
“combination, and engaged TD Securities (USA) LLC as the Company’s exclusive financial advisor. In connection with these actions, the Company expects to incur expenses of between $24.0 million to $29.0 million in total, a substantial portion of which we expect to recognize during the first half of 2025. The anticipated expenses include: severance, benefits, payroll”
Tronox Holdings plc announced a restructuring with charges of approximately $130-160 million affecting Botlek, Netherlands TiO2 plant (approximately 240 impacted permanent staff).
“Tronox estimates incurring restructuring and other related charges of approximately $130-160 million, primarily over the next 18 months, including $55-65 million of non-cash write-downs related to the idling of the facility.”
SUTRO BIOPHARMA, INC. announced a restructuring with charges of approximately $40 million to $45 million affecting luveltamab tazevibulin (luvelta) activities and internal GMP manufacturing facility (approximately 50%).
“The total cash payments and costs related to deprioritizing luvelta-related activities and reducing the workforce are estimated to be approximately $40 million to $45 million, with a significant majority of these amounts expected to be paid in 2025.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.